Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1-700 mg) of BI 638683 Powder in Bottle (PiB) in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1-700 mg) of BI 638683 Powder in Bottle (PiB) in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2015

At a glance

  • Drugs BI 638683 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; Biomarker
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 15 Dec 2010 Trial status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Sep 2010 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 20 Sep 2010 Actual initiation date added to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top